Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Lupron

Executive Summary

Patent office said Lupron (leuprolide) is eligible for two years patent extension. Abbott will be formally issued an extension in one month unless a request for reconsideration of the extension is made.

You may also be interested in...



ROI For US With FDA's Emergency Use Approval Of Cue Health's OTC At-Home COVID-19 Test

After federal agencies invested almost $5600m to ensure Cue Health could scale up production, FDA announces the self-administered test will be available OTC. it's the agency's first emergency use authorization for an at-home molecular diagnostic test available nonprescription.

AstraZeneca & Amgen Seek EU Fast-Track For Severe Asthma Drug

Tezepelumab was among four products that the European Medicines Agency most recently considered for review under its accelerated assessment mechanism.

Alteogen Eyes First-Mover Advantage For Eylea Biosimilar

Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel